about
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactionsModelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.Assessment of the face validity of two pain scales in Kenya: a validation study using cognitive interviewing.Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations.Task Shifting and Skin Punch for the Histologic Diagnosis of Kaposi's Sarcoma in Sub-Saharan Africa: A Public Health Solution to a Public Health Problem.Prevalence and correlates of pain and pain treatment in a western Kenya referral hospital.An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignanciesAIDS-Related Non-Hodgkin's Lymphoma in Sub-Saharan Africa: Current Status and Realities of Therapeutic ApproachRetrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi's sarcoma in western Kenya.Influence of health-insurance access and hospital retention policies on childhood cancer treatment in Kenya.Building cancer nursing skills in a resource-constrained government hospital.A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya.Measuring the glomerular filtration rate in obese individuals without overt kidney disease.Response to Cameron et al "Mind the graph" Semin Oncol. 2018 [in press]Lessons learned from development of docetaxel
P50
Q28482155-436586AB-FA09-4120-853F-B60887E711BBQ34046207-6F7F8A44-764D-4531-A4ED-42AED86AC16EQ34237452-995A9599-6873-42E6-BBC1-98B55286594DQ34482598-0260627E-A08C-48AD-931F-B93D81F08116Q35798331-A5D00A5C-D916-4064-941C-4E6EBA69D90EQ35894809-876A8FC4-786B-400C-814A-5D32BE0F5F23Q36061812-071FDB0A-2036-44A7-A6B2-D1952FF50E13Q36715531-F217C25D-C85A-42A9-99FA-EF36BBB93FDBQ37280653-2503BAA8-B4EF-4FB7-8804-B720325E8A43Q37705726-F9661A0E-0EAD-4480-A33F-719EE73D1079Q38172062-4A2961FC-0224-4737-BCB8-8D0E1391AB47Q38416484-B4AAF1D9-4F9A-4B0B-A3AE-8DF337124084Q46748252-49AFA958-94BF-454C-848F-75F1255FB0A3Q47433938-5BB67EA2-6836-4E01-B60D-91183840B72AQ51450121-887DE1CD-2F81-4BDD-8675-435991D968AFQ55053045-3B44414A-5C24-492D-8DCF-5F909CE095A4Q57813927-E77B8CE6-BF34-4F93-9F46-5A81F4B689DCQ58382477-9D79E4CF-9F22-4495-A4A6-9BEF341DF4CF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Robert Matthew Strother
@ast
Robert Matthew Strother
@en
Robert Matthew Strother
@es
Robert Matthew Strother
@nl
Robert Matthew Strother
@sl
type
label
Robert Matthew Strother
@ast
Robert Matthew Strother
@en
Robert Matthew Strother
@es
Robert Matthew Strother
@nl
Robert Matthew Strother
@sl
prefLabel
Robert Matthew Strother
@ast
Robert Matthew Strother
@en
Robert Matthew Strother
@es
Robert Matthew Strother
@nl
Robert Matthew Strother
@sl
P106
P1153
6602323024
P21
P31
P496
0000-0001-8118-8954